Patent intelligence · EP
EP 2847225
ANTIKÖRPER GEGEN CLAUDIN 18.2 FÜR DIE KREBSDIAGNOSE
ANTIKÖRPER GEGEN CLAUDIN 18.2 FÜR DIE KREBSDIAGNOSE
Patent details — EP 2847225
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Mar 18, 2015
- Expiration
- Mar 13, 2035
- Applicant
- GANYMED PHARMACEUTICALS AG [DE]
- CPC classes
- A61P/3700
Quick answer
EP 2847225 (ANTIKÖRPER GEGEN CLAUDIN 18.2 FÜR DIE KREBSDIAGNOSE) is held by GANYMED PHARMACEUTICALS AG [DE]. Status: granted. Granted Mar 18, 2015. Expires Mar 13, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GANYMED PHARMACEUTICALS AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P/3700
More from GANYMED PHARMACEUTICALS AG [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 2847225?
EP 2847225 (ANTIKÖRPER GEGEN CLAUDIN 18.2 FÜR DIE KREBSDIAGNOSE) is held by GANYMED PHARMACEUTICALS AG [DE]. Status: granted. Granted Mar 18, 2015. Expires Mar 13, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2847225?
GANYMED PHARMACEUTICALS AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 2847225 expire?
Our index shows an expiration date of Mar 13, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.